TARGETED CORRECTION OF A GENETIC DEFECT IN CANCER THERAPY

• 收藏
• 分享

专利权人:

TRT Pharma Inc.

发明人:

Gérald BATIST,Jian Hui WU

申请号：

US13673090

公开号：

US20130143933A1

申请日:

2012.11.09

申请国别(地区):

US

年份:

2013

代理人:

摘要：

The present document describes a cancer mutation-selective chemosensitizer that comprise compounds for restoring association between mutated keap1 protein and Nrf2 protein, and inhibition of Nrf2 functions. The present document also describes composition of matter containing the compounds, as well as methods of medical treatment for treating diseases such as cancer with the compounds.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/